LSE:GSKPharmaceuticals
GSK’s Lynavoy Approval And Licensing Deal Reframe Rare Disease Value Case
GSK (LSE:GSK) has received FDA approval for Lynavoy (linerixibat) as the first treatment in the US for cholestatic pruritus in primary biliary cholangitis.
The approval is based on Phase III data and targets a rare liver disease symptom that significantly affects quality of life.
GSK has signed a licensing agreement granting Alfasigma exclusive worldwide rights to develop, manufacture, and commercialise linerixibat.
Lynavoy adds a rare disease medicine to GSK's portfolio, which already...